Activation of cytotoxic T lymphocytes by self-differentiated myeloid-derived dendritic cells for killing breast cancer cells expressing folate receptor alpha protein

References

• Jazieh K, Bell R, Agarwal N, et al. Novel targeted therapies for metastatic breast cancer. Ann Transl Med. 2020;8(14):907.
   PubMedGoogle Scholar
• Bayraktar S, Batoo S, Okuno S, et al. Immunotherapy in breast cancer. J Carcinog. 2019;18:2.
   PubMedGoogle Scholar
• Gupta GK, Collier AL, Lee D, et al. Perspectives on triple-negative breast cancer: current treatment strategies, unmet needs, and potential targets for future therapies. Cancers (Basel). 2020;12:9.
   Web of Science ®Google Scholar
• Ren D, Cheng H, Wang X, et al. Emerging treatment strategies for breast cancer brain metastasis: from translational therapeutics to real-world experience. Ther Adv Med Oncol. 2020;12:1758835920936151.
   Web of Science ®Google Scholar
• Eccles SA, Aboagye EO, Ali S, et al. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. BCR. 2013;15(5):R92–R.
   PubMed Web of Science ®Google Scholar
• Mouh FZ, Slaoui M, Razine R, et al. Clinicopathological, treatment and event-free survival characteristics in a Moroccan population of triple-negative breast cancer. Breast Cancer. 2020;14:1178223420906428.
   Web of Science ®Google Scholar
• Tao Z, Li S, Ichim TE, et al. Cellular immunotherapy of cancer: an overview and future directions. Immunotherapy. 2017;9(7):589–606.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Yang Y, Wu S, et al. Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer. Bioengineered. 2017;8(4):367–373.
   PubMed Web of Science ®Google Scholar
• Paucek RD, Baltimore D, Li G. The cellular immunotherapy revolution: arming the immune system for precision therapy. Trends Immunol. 2019;40(4):292–309.
   PubMed Web of Science ®Google Scholar
• Wang W, Epler J, Salazar LG, et al. Recognition of breast cancer cells by CD8+ cytotoxic T-cell clones specific for NY-BR-1. Cancer Res. 2006;66(13):6826–6833.
   PubMedGoogle Scholar
• Bernhard H, Neudorfer J, Gebhard K, et al. Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol Immunother. 2008;57(2):271–280.
   PubMed Web of Science ®Google Scholar
• Pincha M, Salguero G, Wedekind D, et al. Lentiviral vectors for induction of self-differentiation and conditional ablation of dendritic cells. Gene Ther. 2011;18(8):750–764.
   PubMedGoogle Scholar
• Pincha M, Sundarasetty BS, Salguero G, et al. Identity, potency, in vivo viability, and scaling up production of lentiviral vector-induced dendritic cells for melanoma immunotherapy. Hum Gene Ther Methods. 2012;23(1):38–55.
   PubMedGoogle Scholar
• Sundarasetty BS, Singh VK, Salguero G, et al. Lentivirus-induced dendritic cells for immunization against high-risk WT1(+) acute myeloid leukemia. Hum Gene Ther. 2013;24(2):220–237.
   PubMed Web of Science ®Google Scholar
• Sundarasetty BS, Chan L, Darling D, et al. Lentivirus-induced ‘Smart’ dendritic cells: pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma. Gene Ther. 2015;22(9):707–720.
   PubMed Web of Science ®Google Scholar
• Panya A, Thepmalee C, Sawasdee N, et al. Cytotoxic activity of effector T cells against cholangiocarcinoma is enhanced by self-differentiated monocyte-derived dendritic cells. Cancer Immunol Immunother. 2018;67(10):1579–1588.
   PubMed Web of Science ®Google Scholar
• Elnakat H, Ratnam M. Role of folate receptor genes in reproduction and related cancers. Front Biosci [Internet]. 2006;2006(11):506–519.
   Google Scholar
• Necela BM, Crozier JA, Andorfer CA, et al. Folate receptor-α (FOLR1) expression and function in triple negative tumors. PLoS ONE. 2015;10(3):e0122209.
   PubMed Web of Science ®Google Scholar
• Luangwattananun P, Junking M, Sujjitjoon J, et al. Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy. Breast Cancer Res Treat. 2021;186(1):25–36.
   PubMed Web of Science ®Google Scholar
• Norton N, Youssef B, Hillman DW, et al. Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients. NPJ Breast Cancer. 2020;6:4.
   PubMed Web of Science ®Google Scholar
• Kelemen LE. The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer. 2006;119(2):243–250.
   PubMed Web of Science ®Google Scholar
• Knutson KL, Krco CJ, Erskine CL, et al. T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. J Clin Oncol. 2006;24(26):4254–4261.
   PubMed Web of Science ®Google Scholar
• O’Shannessy DJ, Somers EB, Maltzman J, et al. Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease. SpringerPlus. 2012;1:22.
   PubMedGoogle Scholar
• Ginter PS, McIntire PJ, Cui X, et al. Folate receptor alpha expression is associated with increased risk of recurrence in triple-negative breast cancer. Clin Breast Cancer. 2017;17(7):544–549.
   PubMed Web of Science ®Google Scholar
• Kalli KR, Block MS, Kasi PM, et al. Folate receptor alpha peptide vaccine generates immunity in breast and ovarian cancer patients. Clin Cancer Res. 2018;24(13):3014–3025.
   PubMed Web of Science ®Google Scholar
• Soule HD, Maloney TM, Wolman SR, et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 1990;50(18):6075–6086.
   PubMed Web of Science ®Google Scholar
• Cribbs AP, Kennedy A, Gregory B, et al. Simplified production and concentration of lentiviral vectors to achieve high transduction in primary human T cells. BMC Biotechnol. 2013;13:98.
   PubMed Web of Science ®Google Scholar
• Boegel S, Löwer M, Bukur T, et al. A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines. Oncoimmunology. 2014;3(8):e954893.
   PubMed Web of Science ®Google Scholar
• Delirezh N, Shojaeefar E, Parvin P, et al. Comparison the effects of two monocyte isolation methods, plastic adherence and magnetic activated cell sorting methods, on phagocytic activity of generated dendritic cells. Cell J. 2013;15(3):218–223.
   PubMed Web of Science ®Google Scholar
• Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29(9):e45.
   PubMed Web of Science ®Google Scholar
• Fu X, Tao L, Rivera A, et al. A simple and sensitive method for measuring tumor-specific T cell cytotoxicity. Plos One. 2010;5(7):e11867.
   PubMed Web of Science ®Google Scholar
• Fragomeni SM, Sciallis A, Jeruss JS. Molecular subtypes and local-regional control of breast cancer. Surg Oncol Clin N Am. 2018;27(1):95–120.
   PubMed Web of Science ®Google Scholar
• Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Med Press). 2019;11:151–164.
   PubMed Web of Science ®Google Scholar
• Wculek SK, Cueto FJ, Mujal AM, et al. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20(1):7–24.
   PubMed Web of Science ®Google Scholar
• Neidhardt-Berard E-M, Berard F, Banchereau J, et al. Dendritic cells loaded with killed breast cancer cells induce differentiation of tumor-specific cytotoxic T lymphocytes. BCR. 2004;6(4):R322–R8.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wang J, Tacha DE, et al. Folate receptor alpha associated with triple-negative breast cancer and poor prognosis. Arch Pathol Lab Med. 2014;138(7):890–895.
   PubMed Web of Science ®Google Scholar
• Scaranti M, Cojocaru EA-O, Banerjee S, et al. Exploiting the folate receptor α in oncology. (1759-4782 (Electronic)).
   Google Scholar
• Kim DK, Lee TV, Castilleja A, et al. Folate binding protein peptide 191-199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients. Anticancer Res. 1999;19(4b):2907–2916.
   PubMedGoogle Scholar
• Liu Z, Chen O, Wall JBJ, et al. Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector. Sci Rep. 2017;7(1):2193.
   PubMedGoogle Scholar
• Mbongue JC, Nieves HA, Torrez TW, et al. The role of dendritic cell maturation in the induction of insulin-dependent diabetes mellitus. Front Immunol. 2017;8:327.
   PubMed Web of Science ®Google Scholar
• Ma DY, Clark EA. The role of CD40 and CD154/CD40L in dendritic cells. Semin Immunol. 2009;21(5):265–272.
   PubMed Web of Science ®Google Scholar
• Henry CJ, Ornelles DA, Mitchell LM, et al. IL-12 produced by dendritic cells augments CD8+ T cell activation through the production of the chemokines CCL1 and CCL17. J Immunol. 2008;181(12):8576–8584.
   PubMed Web of Science ®Google Scholar
• Ahrends T, Busselaar J, Severson TM, et al. CD4(+) T cell help creates memory CD8(+) T cells with innate and help-independent recall capacities. Nat Commun. 2019;10(1):5531.
   PubMedGoogle Scholar
• Drake A, Kaur M, Iliopoulou BP, et al. Interleukins 7 and 15 maintain human T cell proliferative capacity through STAT5 signaling. PloS One. 2016;11(11):e0166280–e.
   PubMedGoogle Scholar
• Smith KA. Interleukin-2: inception, impact, and implications. Science (New York, NY). 1988;240(4856):1169–1176.
   Google Scholar
• Tai Y, Wang Q, Korner H, et al. Molecular mechanisms of T cells activation by dendritic cells in autoimmune diseases. Front Pharmacol. 2018;9:642.
   PubMed Web of Science ®Google Scholar
• Cui W, Kaech SM. Generation of effector CD8+ T cells and their conversion to memory T cells. Immunol Rev. 2010;236:151–166.
   PubMed Web of Science ®Google Scholar
• Bhat P, Leggatt G, Waterhouse N, et al. Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity. Cell Death Dis. 2017;8(6):e2836–e.
   PubMedGoogle Scholar
• Jorgovanovic D, Song M, Wang L, et al. Roles of IFN-γ in tumor progression and regression: a review. Biomark Res. 2020;8(1):49.
   PubMed Web of Science ®Google Scholar
• Edmondson R, Broglie JJ, Adcock AF, et al. Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev Technol. 2014;12(4):207–218.
   PubMed Web of Science ®Google Scholar
• Gottschalk E, Czech E, Aksoy BA, et al. Towards a scaled-up T cell-mediated cytotoxicity assay in 3D cell culture using microscopy. bioRxiv. 2019;842039.
   Google Scholar
• Ye Q, Han X, Wu Z. Bioinformatics analysis to screen key prognostic genes in the breast cancer tumor microenvironment. Bioengineered. 2020;11(1):1280–1300.
   PubMed Web of Science ®Google Scholar
• Chun BM, Page DB, McArthur HL. Combination immunotherapy strategies in breast cancer. Curr Breast Cancer Rep. 2019;11(4):228–240.
   Web of Science ®Google Scholar
• McArthur HL, Page DB. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy. Clin Adv Hematol Oncol. 2016;14(11):922–933.
   PubMed Web of Science ®Google Scholar